COPD Management

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

GOLD Executive Summary Key Revisions

Efficacy and Safety of SUN-101 in Moderate-To-Very-Severe COPD: GOLDEN 3 and 4

Long-Term Safety of SUN-101 GOLDEN-5 Study

Revefenacin Once-Daily LAMA for Nebulization

Safety Outcomes on Long-Term Use of Formoterol Fumarate Inhalation Solution

LAMA/LABA Dual Therapies GOLD Executive Summary recommendation[a] For patients with symptoms on a single long-acting bronchodilator, step-up to dual- bronchodilator therapy rather than adding on an inhaled-corticosteroid Currently approved LAMA/LABA therapies in a single inhaler Glycopyrrolate/formoterol fumarate Glycopyrrolate/indacaterol Tiotropium/olodaterol Umeclidinium bromide/vilanterol a. Vogelmeier CF, et al. Am J Respir Crit Care Med. 2017;195:557-582.

TONADO Study: Long-Term Safety of Tiotropium/Olodaterol in Elderly Patients

Lung Function Benefits of Glycopyrrolate/Formoterol MDI With and Without Valved Holding Chamber

FLIGHT Subanalysis Studies

GOLD Recommendations Escalating to Triple Therapy

Single Inhaler Triple Therapy vs Dual Therapy Subgroup Analysis of 24-Hour Serial Spirometry for the FULFIL Study

TRINITY Study Extrafine Fixed Triple Therapy

Exploring Practice Gaps in Prescribing Inhalation Delivery Devices for the Management of COPD: Results From the DMaD Survey

Is There a Communication Gap Between Patients and Pulmonologists in Delivery Device Selection?

Are Patients and Physicians on the Same Page Regarding Nebulizer Therapy?

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)